CBD of Denver Inc. (CBDD)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CBDD steht fuer CBD of Denver Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 51/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026CBD of Denver Inc. (CBDD) Gesundheitswesen & Pipeline-Uebersicht
CBD of Denver Inc. is a cannabidiol (CBD) product company involved in the research, development, and distribution of premium hemp extract products. Operating as a subsidiary of Swiss Industry Ventures AG, the company focuses on commercializing CBD products within the specialty and generic drug manufacturing sector.
Investmentthese
CBD of Denver Inc. presents a speculative investment opportunity within the rapidly evolving CBD market. The company's focus on premium hemp extract products and its position as a subsidiary of Swiss Industry Ventures AG could provide a competitive edge. However, the company's financial performance and market capitalization of $0.00B indicate significant risks. A gross margin of 27.1% suggests potential profitability challenges. The negative beta of -10.69 indicates an inverse correlation with the market, which could be a double-edged sword. Growth catalysts include potential expansion into new product lines and geographic markets. Investors should carefully evaluate the company's OTC status and associated risks before considering an investment.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B reflects the company's small size and potential volatility.
- Gross Margin of 27.1% indicates the profitability of CBDD's core operations.
- Beta of -10.69 suggests an inverse correlation with the broader market.
- CBDD operates as a subsidiary of Swiss Industry Ventures AG.
- CBDD focuses on the development and commercialization of cannabidiol (CBD) products.
Staerken
- Focus on premium hemp extract products.
- Subsidiary of Swiss Industry Ventures AG.
- Established presence in the CBD market.
- Commitment to research and development.
Schwaechen
- Small market capitalization.
- Limited financial resources.
- Dependence on the CBD market.
- OTC market listing.
Katalysatoren
- Upcoming: Potential expansion into new therapeutic areas.
- Upcoming: Geographic expansion into new markets.
- Upcoming: Development of innovative CBD products.
- Ongoing: Strategic partnerships and acquisitions.
- Ongoing: Focus on quality and compliance.
Risiken
- Potential: Intense competition in the CBD market.
- Potential: Evolving regulations and consumer preferences.
- Potential: Negative publicity or product recalls.
- Potential: Fluctuations in the price of hemp extract.
- Ongoing: Limited financial resources.
Wachstumschancen
- Expansion into New Therapeutic Areas: CBD of Denver Inc. has the opportunity to expand its product line into new therapeutic areas, such as pain management, anxiety relief, and sleep disorders. The market for CBD-based therapeutic products is growing rapidly, driven by increasing consumer awareness and scientific research. By developing and commercializing targeted CBD formulations, CBD of Denver Inc. can tap into this lucrative market segment and differentiate itself from competitors. This expansion could involve partnerships with healthcare providers and research institutions. The timeline for this growth opportunity is estimated at 2-3 years, with a potential market size of $5 billion.
- Geographic Expansion: CBD of Denver Inc. can pursue geographic expansion into new markets, both domestically and internationally. The global CBD market is highly fragmented, with significant growth potential in emerging markets. By establishing distribution partnerships and tailoring its product offerings to local preferences, CBD of Denver Inc. can expand its reach and increase its revenue. This expansion could involve entering into joint ventures or acquiring local CBD companies. The timeline for this growth opportunity is estimated at 3-5 years, with a potential market size of $10 billion.
- Development of Innovative CBD Products: CBD of Denver Inc. can invest in research and development to create innovative CBD products with enhanced efficacy and bioavailability. This could involve developing novel formulations, delivery systems, and extraction methods. By patenting its innovations and establishing a strong intellectual property portfolio, CBD of Denver Inc. can gain a competitive advantage and attract strategic partners. The timeline for this growth opportunity is estimated at 2-4 years, with a potential market size of $3 billion.
- Strategic Partnerships and Acquisitions: CBD of Denver Inc. can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with established healthcare companies, retailers, or distributors. By acquiring complementary businesses, CBD of Denver Inc. can gain access to new technologies, products, and distribution channels. The timeline for this growth opportunity is estimated at 1-3 years, with a potential market size of $2 billion.
- Focus on Quality and Compliance: CBD of Denver Inc. can differentiate itself by focusing on product quality and regulatory compliance. This involves implementing rigorous quality control measures, obtaining certifications, and adhering to all applicable regulations. By building a reputation for quality and compliance, CBD of Denver Inc. can gain the trust of consumers and healthcare providers. The timeline for this growth opportunity is ongoing, with a potential market size of $1 billion.
Chancen
- Expansion into new therapeutic areas.
- Geographic expansion into new markets.
- Development of innovative CBD products.
- Strategic partnerships and acquisitions.
Risiken
- Intense competition in the CBD market.
- Evolving regulations and consumer preferences.
- Potential for negative publicity or product recalls.
- Fluctuations in the price of hemp extract.
Wettbewerbsvorteile
- Proprietary CBD formulations and extraction methods.
- Established distribution network.
- Strong brand reputation for quality and compliance.
- Strategic partnerships with key players in the healthcare and wellness industries.
Ueber CBDD
CBD of Denver Inc., formerly known as Verde Media Group, Inc., was rebranded in 2018 to focus on the burgeoning cannabidiol (CBD) market. The company is dedicated to the research, development, and commercialization of a range of CBD products. Its core business revolves around the creation and distribution of premium hemp extract products, catering to a growing demand for CBD-based solutions. Headquartered in Centennial, Colorado, CBD of Denver Inc. operates as a subsidiary of Swiss Industry Ventures AG, leveraging its parent company's resources and expertise. The company's evolution reflects the increasing acceptance and market potential of CBD in various applications, from wellness to potential therapeutic uses. CBD of Denver Inc. aims to establish itself as a key player in the CBD market by focusing on product quality, innovation, and strategic distribution partnerships. The company's commitment to research and development underscores its ambition to stay at the forefront of CBD advancements and capitalize on emerging opportunities within the healthcare and wellness sectors. CBD of Denver Inc. distributes its products through various channels, targeting both retail consumers and potential business-to-business partnerships.
Was das Unternehmen tut
- Develops and commercializes cannabidiol (CBD) products.
- Engages in the research of hemp extract products.
- Distributes premium hemp extract products.
- Focuses on the wellness and potential therapeutic applications of CBD.
- Operates as a subsidiary of Swiss Industry Ventures AG.
- Aims to establish a strong presence in the CBD market.
Geschaeftsmodell
- Develops and formulates CBD products.
- Manufactures or outsources the production of CBD products.
- Distributes CBD products through various channels, including retail and online sales.
- Generates revenue from the sale of CBD products.
Branchenkontext
CBD of Denver Inc. operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing significant growth due to the increasing acceptance and legalization of cannabis and CBD products. The market is characterized by intense competition, with numerous companies vying for market share. The industry is also subject to evolving regulations and consumer preferences. CBD of Denver Inc.'s success depends on its ability to differentiate its products, navigate the regulatory landscape, and establish strong distribution channels. The global CBD market is projected to reach billions of dollars in the coming years, presenting both opportunities and challenges for companies like CBD of Denver Inc.
Wichtige Kunden
- Consumers seeking wellness and therapeutic benefits from CBD.
- Retailers and distributors of CBD products.
- Healthcare providers interested in CBD-based solutions.
- Businesses seeking to incorporate CBD into their products.
Finanzdaten
Chart & Info
CBD of Denver Inc. (CBDD) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CBDD verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CBDD.
Kursziele
Wall-Street-Kurszielanalyse fuer CBDD.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CBDD auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
CBDD OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that CBD of Denver Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, which increases investment risk. Investing in companies on the OTC Other tier requires a high degree of due diligence and risk tolerance due to the potential for fraud, lack of liquidity, and limited information availability. These companies are not required to be SEC reporting.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Potential for fraud or manipulation.
- Lack of liquidity.
- High price volatility.
- Limited regulatory oversight.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor.
- Confirm the company's good standing with the Secretary of State.
- Company is a subsidiary of Swiss Industry Ventures AG.
- Company has been in operation since 2018.
- Company focuses on a growing market segment (CBD).
- Company has a defined business model.
- Company has a physical headquarters in Centennial, Colorado.
CBD of Denver Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CBDD?
CBD of Denver Inc. (CBDD) currently holds an AI score of 51/100, indicating moderate score. Key strength: Focus on premium hemp extract products.. Primary risk to monitor: Potential: Intense competition in the CBD market.. This is not financial advice.
How frequently does CBDD data refresh on this page?
CBDD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBDD's recent stock price performance?
Recent price movement in CBD of Denver Inc. (CBDD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on premium hemp extract products.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBDD overvalued or undervalued right now?
Determining whether CBD of Denver Inc. (CBDD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBDD?
Before investing in CBD of Denver Inc. (CBDD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CBDD to a portfolio?
Potential reasons to consider CBD of Denver Inc. (CBDD) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Focus on premium hemp extract products.. Additionally: Subsidiary of Swiss Industry Ventures AG.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CBDD?
Yes, most major brokerages offer fractional shares of CBD of Denver Inc. (CBDD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CBDD's earnings and financial reports?
CBD of Denver Inc. (CBDD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CBDD earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is limited due to the company's OTC listing and disclosure status.
- AI analysis is pending for CBDD.